INVESTIGADORES
ENRIZENRIZ] ricardoricardo] danieldaniel]
artículos
Título:
Quinoline analogs of 2-aminoindane as potential central dopaminergic agents
Autor/es:
ANGEL, JORGE E.; ENRIZENRIZ], RICARDORICARDO] D.; BALZA, KATHERINDEL C.; ANGEL, LIGIA B.; PERDOMO, LUÍS E.; RODRÍGUEZ, LUCIA CH.; DABIAN, AKRAM S.; DEL C. MIGLIORE, BIAGINA; RAMÍREZ, MARÍA M.; ORTEGA, JOSÉ G.; CHARRIS, JAIME E.; ISRAEL, ANITA.; DEL R. GARRIDO, MARÍA; LÓPEZ, SIMON E.; ROJAS, SEBASTIAN; ANDUJAR, SEBASTIAN A.
Revista:
MEDICINAL CHEMISTRY RESEARCH
Editorial:
BIRKHAUSER BOSTON INC
Referencias:
Año: 2019 vol. 28 p. 1168 - 1168
ISSN:
1054-2523
Resumen:
Neurodegenerative disorders such as Parkinson and Huntington Chorea are related with damage to the central dopaminergic system. On the purpose to find new drugs able to re-establish the imbalance on the dopaminergic neurotransmission in the central nervous system and counteract some of the neurodegenerative sicknesses, we have designed, synthesized, pharmacologically evaluated, and studied through molecular modeling,2-aminoindane-quinoline analog derivatives (1?5). Pharmacological studies made on the central nervous system through ICV (intracerebroventricular) and IS (intrastriatal), of compounds (1?5) showed agonistic activity by the activation of dopaminergic mechanisms on the central nervous system. The corresponding molecular modeling study permitted us not only to explain the differential behavior of studied compounds, but also to understand whichmolecular interactions are responsible to stabilize the different complexes formed between those compounds and the D2 receptor. These results validate our medicinal chemical approach in different aspects: the receptor model used, the responsible fragment inserted within the structure of the compounds capable of interacting with the receptor, the complementary functional groups that facilitate the expected response and the pharmacological administration routes. All these aspects are important for the design of this type of compounds as potential anti-Parkinson and/or anti-Huntington agents.
rds']